Company Reports Q4 Revenue of $650,000, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy ABSI?
Reports Q4 revenue $650,000, consensus $1.38M. "Over the past year, we advanced ABS-201 from preclinical to three dosed cohorts in our HEADLINE trial with favorable emerging safety data, extending our track record of moving from AI design to clinic in approximately two years at a fraction of industry cost," said Sean McClain, founder and CEO. "Dr. Ransi Somaratne has joined as our first Chief Medical Officer to lead clinical execution and strategy. We are focused on delivering interim proof-of-concept data in the second half of 2026 and initiating our endometriosis Phase 2 by year-end. In AGA and endometriosis, there is a significant unmet need, as no approved disease-modifying therapeutic options exist for these patients. This is the kind of whitespace where we believe our AI-native drug creation strategy can generate the most value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABSI
Wall Street analysts forecast ABSI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.760
Low
4.32
Averages
7.66
High
10.00
Current: 2.760
Low
4.32
Averages
7.66
High
10.00
About ABSI
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Absci (ABSI) Q4 2025 Earnings Call Transcript
See More
ABSCI STOCK DROPS 4.9% FOLLOWING Q4 RESULTS
- Company Performance: The company reported a 4.9% decline in its stock value following the release of its Q4 results.
- Market Reaction: Investors reacted negatively to the earnings report, leading to a significant drop in share prices.
- Future Outlook: Analysts are concerned about the implications of the Q4 results on the company's future performance and growth potential.
- Investor Sentiment: The decline in stock value reflects a broader uncertainty among investors regarding the company's strategic direction.
See More
Absci Corp Reports Q4 Highlights and Future Prospects
- Financial Performance: In Q4 2025, Absci Corp reported revenue of $700,000, with R&D expenses rising to $25.3 million from $18.4 million year-over-year, indicating a commitment to innovation despite potential short-term profitability pressures due to increased spending.
- Cash Position: As of December 31, 2025, the company held $144.3 million in cash, cash equivalents, and marketable securities, down from $152.5 million on September 30, 2025, yet sufficient to fund operations into the first half of 2028, reflecting strong financial management.
- Clinical Progress: ABS-201 is showing promising results in clinical trials with favorable emerging safety data and has expanded into endometriosis, a second multibillion-dollar indication, highlighting its market potential and potential new revenue streams for the company.
- Market Competition: The success of ABS-201 hinges on achieving efficacy comparable to or exceeding high-dose oral minoxidil, while the company faces significant competition in the androgenetic alopecia market, with other treatments gaining traction that could impact its market share.
See More
Absci Corporation Reports Strong Q4 2025 Earnings and Clinical Advancements
- Clinical Advancements: Absci's ABS-201 has entered clinical trials with the first single ascending dose cohorts dosed, and preliminary safety data shows promise, indicating the drug's potential in treating androgenetic alopecia and endometriosis.
- Financial Performance: The company reported $700,000 in revenue for Q4, with R&D expenses rising to $25.3 million, reflecting ongoing investment in internal programs, while ending the year with $144.3 million in cash and equivalents, ensuring operational funding for the coming years.
- Strategic Outlook: Absci anticipates sharing preliminary safety and pharmacokinetic data for ABS-201 in the first half of 2026, with 13-week proof-of-concept data in the second half, and plans to initiate a Phase II clinical trial for endometriosis in Q4 2026.
- Market Opportunity: Management highlighted a potential $25 billion annual addressable market for ABS-201 in the U.S., emphasizing the product's commercial prospects and market potential, while continuing discussions with pharmaceutical companies for platform partnerships.
See More
ABSCI CORP REPORTS $0.7 MILLION IN REVENUE FOR Q4
- Company Overview: The company reported a revenue of $0.7 million for the fourth quarter.
- Financial Performance: The revenue figure indicates the company's financial performance during this specific period.
See More
ABSCI STOCK FALLS 5.1% IN AFTER-HOURS TRADING FOLLOWING QUARTERLY RESULTS RELEASE
- Stock Performance: Shares dropped by 5.1% in extended trading following the release of quarterly results.
- Quarterly Results: The decline in stock price occurred after the company posted its latest financial performance.
See More
Absci (ABSI) Q4 2025 Earnings Call Transcript
See More
ABSCI STOCK DROPS 4.9% FOLLOWING Q4 RESULTS
- Company Performance: The company reported a 4.9% decline in its stock value following the release of its Q4 results.
- Market Reaction: Investors reacted negatively to the earnings report, leading to a significant drop in share prices.
- Future Outlook: Analysts are concerned about the implications of the Q4 results on the company's future performance and growth potential.
- Investor Sentiment: The decline in stock value reflects a broader uncertainty among investors regarding the company's strategic direction.
See More
Absci Corp Reports Q4 Highlights and Future Prospects
- Financial Performance: In Q4 2025, Absci Corp reported revenue of $700,000, with R&D expenses rising to $25.3 million from $18.4 million year-over-year, indicating a commitment to innovation despite potential short-term profitability pressures due to increased spending.
- Cash Position: As of December 31, 2025, the company held $144.3 million in cash, cash equivalents, and marketable securities, down from $152.5 million on September 30, 2025, yet sufficient to fund operations into the first half of 2028, reflecting strong financial management.
- Clinical Progress: ABS-201 is showing promising results in clinical trials with favorable emerging safety data and has expanded into endometriosis, a second multibillion-dollar indication, highlighting its market potential and potential new revenue streams for the company.
- Market Competition: The success of ABS-201 hinges on achieving efficacy comparable to or exceeding high-dose oral minoxidil, while the company faces significant competition in the androgenetic alopecia market, with other treatments gaining traction that could impact its market share.
See More
Absci Corporation Reports Strong Q4 2025 Earnings and Clinical Advancements
- Clinical Advancements: Absci's ABS-201 has entered clinical trials with the first single ascending dose cohorts dosed, and preliminary safety data shows promise, indicating the drug's potential in treating androgenetic alopecia and endometriosis.
- Financial Performance: The company reported $700,000 in revenue for Q4, with R&D expenses rising to $25.3 million, reflecting ongoing investment in internal programs, while ending the year with $144.3 million in cash and equivalents, ensuring operational funding for the coming years.
- Strategic Outlook: Absci anticipates sharing preliminary safety and pharmacokinetic data for ABS-201 in the first half of 2026, with 13-week proof-of-concept data in the second half, and plans to initiate a Phase II clinical trial for endometriosis in Q4 2026.
- Market Opportunity: Management highlighted a potential $25 billion annual addressable market for ABS-201 in the U.S., emphasizing the product's commercial prospects and market potential, while continuing discussions with pharmaceutical companies for platform partnerships.
See More
ABSCI CORP REPORTS $0.7 MILLION IN REVENUE FOR Q4
- Company Overview: The company reported a revenue of $0.7 million for the fourth quarter.
- Financial Performance: The revenue figure indicates the company's financial performance during this specific period.
See More
ABSCI STOCK FALLS 5.1% IN AFTER-HOURS TRADING FOLLOWING QUARTERLY RESULTS RELEASE
- Stock Performance: Shares dropped by 5.1% in extended trading following the release of quarterly results.
- Quarterly Results: The decline in stock price occurred after the company posted its latest financial performance.
See More
